GSK2334470
GSK2334470结构式
|
常用名 | GSK2334470 | 英文名 | GSK2334470 |
|---|---|---|---|---|
| CAS号 | 1227911-45-6 | 分子量 | 462.591 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C25H34N8O | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
|
Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Oncotarget 6(7) , 5134-46, (2015) Dual PI3K/mTOR(phosphatidylinositol 3-kinase/mammalian target of rapamycin) inhibitors are being evaluated clinically for the treatment of tumors with a hyperactivated PI3K/mTOR pathway. However, unexpected outcomes were obtained in clinical studies of cancer... |
|
|
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Breast Cancer Res. 18 , 41, (2016) The PI3K pathway is hyperactivated in many cancers, including 70 % of breast cancers. Pan- and isoform-specific inhibitors of the PI3K pathway are currently being evaluated in clinical trials. However, the clinical responses to PI3K inhibitors when used as si... |
|
|
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.
Oncotarget 5(10) , 3145-58, (2014) Our understanding of breast cancer heterogeneity at the protein level is limited despite proteins being the ultimate effectors of cellular functions. We investigated the heterogeneity of breast cancer (41 primary tumors and 15 breast cancer cell lines) at the... |